Lv1
40 积分 2025-10-20 加入
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
1个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
3个月前
已完结
Antibody–drug conjugates in lung cancer: current landscape and future perspectives
4个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
5个月前
已完结
Improving outcomes of patients with pancreatic cancer
7个月前
已完结
Pancreatic cancer
7个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
10个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC
10个月前
已完结
皖公网安备34019202002308
